Scott Smith

Biovail Pharmaceuticals, Inc. researches and develops pharmaceutical medicines. The company products include Wellbutrin SR, Retavase, Zyban and Tiazac XC in Canada and Zovirax Ointment and Zovirax Cream in the United States. The company is headquartered in Bridgewater, NJ.

F-Star Therapeutics, Inc. engages in discovery and development of a novel class of therapeutics using its proprietary small molecule nucleic acid hybrid (SMNH) chemistry platform. Its products are used for the treatment of viral infections, inflammatory diseases, and certain cancers. The company was founded by Douglas J. Jensen and Radhakrishnan P. Iyer on October 7, 2002 and is headquartered in Hopkinton, MA.

Apexigen America, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery and development of innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology. Its product portfolio includes humanized antibodies, targeting diseases such as cancer, inflammatory diseases and ophthalmic disease. The company was founded by Xiao Dong Yang in July 2010 and is headquartered in San Carlos, CA.

Triumvira Immunologics, Inc. develops and manufactures pharmaceutical products. The company was founded by Jonathan Bramson in 2015 and is headquartered in Hamilton, Canada.

Biovail Pharmaceuticals Canada sells pharmaceutical products. The private company is based in Mississauga, Canada.

Refuge Biotechnologies, Inc. develops therapeutic cells. It is leveraging gene engineering technologies known as CRISPR interference (CRISPRi) and CRISPR activation (CRISPRa) to develop therapeutic cells that are programmed to make decisions inside the patient’s body. The firms programs include RB-1916, RB-H21 and RB-M1. The company was founded by Stanley Qi, David R. Parkinson and Bing C. Wang and is headquartered in Menlo Park, CA.

Triumvira Immunologics USA, Inc. develops and manufactures novel T cell therapies for cancer. The company is based in Austin, TX and has subsidiaries in Canada. Paul Lammers has been the CEO of the company since 2018.

Himalaya Therapeutics is a Caymanian clinical-stage biotechnology company that is advancing its pipeline of novel monoclonal antibody and other protein therapeutic product candidates through clinical trials. The company is based in George Town, Cayman Islands, with operations in Taiwan and China. The company's product candidates have been developed using cab technology, which is protected by more than 500 issued and pending patents. Himalaya has two cab programs currently in phase 2 clinical testing in Taiwan\: BA3011, a novel conditionally active AXL-targeted antibody-drug conjugate (CAB-AXL-ADC), and BA3021, a novel conditionally active ROR2-targeted antibody-drug conjugate (CAB-ROR2-ADC). Himalaya has a co-development and collaboration agreement for an investigational CAB CTLA-4 antibody, BA3071, with BeiGene Ltd. for its development, manufacturing, and commercialization in Greater China. The company was founded by Carolyn Anderson Short and Jay M. Short, and the CEO is Brian Zhang.